Video

What To Know About Aducanumab and Slowing the Progression of Alzheimer Disease

Pharmacy Times spoke to Dr. Douglas Scharre, neurologist and director of the division of Cognitive Neurology at Ohio State Wexner Medical Center, about the latest FDA approved drug for Alzheimer disease.

Pharmacy Times spoke to Dr.Douglas Scharre, neurologist and director of the division of Cognitive Neurology at Ohio State Wexner Medical Center, about the latest FDA approved drug for Alzheimer disease.

Related Videos
Pharmacist and patient in a community pharmacy -- Image credit: Gorodenkoff | stock.adobe.com
X-ray image of human brain with neurons -- Image credit: Who is Danny | stock.adobe.com
Related Content
Huntington disease -- Image credit: Dr_Microbe | stock.adobe.com
April 21st 2025

FDA Grants Breakthrough Therapy Designation to AMT-130 to Treat Huntington Disease

Gillian McGovern, Associate Editor
Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment
September 26th 2024

Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment

Health care professional looking at scans of brain -- Image credit: sudok1 | stock.adobe.com
April 11th 2025

Nipocalimab Sustains Disease Control Over 84 Weeks in Patients With gMG

Gillian McGovern, Associate Editor
Pharmacy Focus: Alzheimer Drug Pipeline Expands, Promising Therapies in Development
August 23rd 2024

Pharmacy Focus: Alzheimer Drug Pipeline Expands, Promising Therapies in Development

Ashley Gallagher, Editor
Stethoscope and paper with Huntington's Disease written -- Image credit: syahrir | stock.adobe.com
April 9th 2025

AAN 2025: Pridopidine Shows Sustained Benefits on Progression, Cognition, and Motor Function in Patients With HD

Gillian McGovern, Associate Editor
Child with a migraine -- Image credit: irena_geo | stock.adobe.com
April 8th 2025

AAN 2025: Fremanezumab Superior to Placebo in Reducing Monthly Migraine Days in Children and Adolescents

Gillian McGovern, Associate Editor